Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERT-002 in advanced solid tumors and MET-altered non-small cell lung cancer
NL-OMON61229Phase 2Active, not recruiting
- Sponsor
- Pierre Fabre Laboratories
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of vert-002 in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Pierre Fabre Laboratories. Primary endpoints: Safety, Tolerability and 4 more. Started Mar 2025; status: active, not recruiting.
02
Drugs
vert-002
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON61229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61229.